[
  {
    "date": "2023-12-30",
    "symbol": "QNRX",
    "period": "FY",
    "documenttype": "10-K",
    "documenttransitionreport": "false",
    "documentperiodenddate": "2023-12-31",
    "entityfilenumber": "001-37846",
    "entityregistrantname": "Quoin Pharmaceuticals, Ltd.",
    "entityincorporationstatecountrycode": "L3",
    "entitytaxidentificationnumber": "92-2593104",
    "entityaddressaddressline1": "42127 Pleasant Forest Court",
    "entityaddressstateorprovince": "VA",
    "entityaddresscityortown": "Ashburn",
    "entityaddresspostalzipcode": 20148,
    "cityareacode": 703,
    "localphonenumber": "980-4182",
    "security12btitle": "American Depositary Shares",
    "tradingsymbol": "QNRX",
    "securityexchangename": "NASDAQ",
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityinteractivedatacurrent": "Yes",
    "entityfilercategory": "Non-accelerated Filer",
    "entitysmallbusiness": "true",
    "entityemerginggrowthcompany": "false",
    "icfrauditorattestationflag": "false",
    "documentfinstmterrorcorrectionflag": "false",
    "entityshellcompany": "false",
    "currentfiscalyearenddate": "--12-31",
    "amendmentflag": "false",
    "entitycentralindexkey": 1671502,
    "documentfiscalyearfocus": 2023,
    "documentfiscalperiodfocus": "FY",
    "documentannualreport": "true",
    "auditorname": "Marcum LLP",
    "auditorlocation": "East Hanover, New Jersey",
    "auditorfirmid": 688,
    "cashandcashequivalentsatcarryingvalue": 2401198,
    "investments": 8293663,
    "prepaidexpenseandotherassetscurrent": 591034,
    "assetscurrent": 11285895,
    "prepaidexpensenoncurrent": 300000,
    "intangibleassetsnetexcludinggoodwill": 583334,
    "assets": 12169229,
    "accountspayablecurrent": 526523,
    "accruedliabilitiescurrent": 1308706,
    "interestpayablecurrentandnoncurrent": 1146251,
    "otherliabilitiescurrent": 600000,
    "otherliabilitycurrentrelatedpartytypeextensibleenumeration": "http://fasb.org/srt/2023#OfficerMember",
    "liabilitiescurrent": 3581480,
    "otherliabilitiesnoncurrent": 2923733,
    "otherliabilitynoncurrentrelatedpartytypeextensibleenumeration": "http://fasb.org/srt/2023#OfficerMember",
    "liabilities": 6505213,
    "additionalpaidincapital": 51867336,
    "retainedearningsaccumulateddeficit": -46203320,
    "stockholdersequity": 5664016,
    "liabilitiesandstockholdersequity": 12169229,
    "commonstocksharesauthorized": 100000000,
    "commonstocksharesissued": 987220,
    "commonstocksharesoutstanding": 987220,
    "sellinggeneralandadministrativeexpense": 6070517,
    "researchanddevelopmentexpense": 3307987,
    "operatingcostsandexpenses": 9378504,
    "unrealizedgainlossonderivatives": -2683,
    "realizedandaccruedinterestincome": 694614,
    "nonoperatingincomeexpense": 691931,
    "netincomeloss": -8686573,
    "netincomelossavailabletocommonstockholdersbasic": -8686573,
    "earningspersharebasic": -9.64,
    "earningspersharediluted": -9.64,
    "weightedaveragenumberofsharesoutstandingbasic": 900919,
    "weightedaveragenumberofdilutedsharesoutstanding": 900919,
    "adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalue": 1094549,
    "treasurystockretiredcostmethodamount": 2932000,
    "stockissuedduringperiodvaluenewissues": 5849266,
    "stockissuedduringperiodsharesnewissues": 583333,
    "profitloss": -8686573,
    "sharebasedcompensation": 1094549,
    "amortizationofintangibleassets": 103706,
    "assetimpairmentcharges": 17521,
    "unrealizedgainlossoninvestments": 489079,
    "increasedecreaseinaccountspayableandaccruedexpenses": 53924,
    "increasedecreaseinprepaidexpense": -41523,
    "netcashprovidedbyusedinoperatingactivities": -7864429,
    "paymentstoacquireinvestments": 18090684,
    "proceedsfromsalematurityandcollectionsofinvestments": 20279000,
    "netcashprovidedbyusedininvestingactivities": 2188316,
    "paymentsforproceedsfromdeferredloancosts": 32583,
    "repaymentsofrelatedpartydebt": 600000,
    "netproceedsfromissuanceofcommonstock": 5849266,
    "netcashprovidedbyusedinfinancingactivities": 5216683,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseexcludingexchangerateeffect": -459430,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalents": 2401198,
    "offeringexpensesassociatedwithwarrantmodification": 238231,
    "accumulatedothercomprehensiveincomelossnetoftax": 46200000,
    "tradingsecurities": 8300000,
    "investmentsmaturityterm": "P4M",
    "finitelivedintangibleassetusefullife": "P10Y",
    "goodwillandintangibleassetimpairment": 1,
    "antidilutivesecuritiesexcludedfromcomputationofearningspershareamount": 864081,
    "warrantsandrightsoutstandingterm": "P5Y",
    "convertiblenotespayablenumberofremainingnoteholdersreceiveconsideration": 3,
    "warrantsandrightsoutstanding": 8293663,
    "commonstockcapitalsharesreservedforfutureissuance": 319397,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnumberofsharesavailableforgrant": 41386,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": 278011,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodgross": 252416,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisablenumber": 7382,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 25.34,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageexerciseprice": 6.62,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageexerciseprice": 210,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2": "P9Y8M4D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageremainingcontractualterm1": "P8Y4M17D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrate": 1.106,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestrate": 0.048,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": "P6Y4M24D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexerciseprice": 6.62,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsfairvalueofamericandepositaryshare": 4.31,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsestimatedfairvalueofoption": 3.6,
    "allocatedsharebasedcompensationexpense": 1090000,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognizedstockoptions": 3,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognizedperiodforrecognition1": "P3Y8M12D",
    "prepaidresearchanddevelopmentcosts": 447979,
    "prepaidinsurance": 401972,
    "otherprepaidexpensecurrent": 8500,
    "deferredofferingcosts": 32583,
    "prepaidexpensecurrentandnoncurrent": 891034,
    "prepaidexpensecurrent": 591034,
    "accruedresearchcontractexpensecurrent": 358287,
    "accruedsalariescurrent": 804156,
    "accruedpayrolltaxescurrent": 93989,
    "accruedprofessionalfeescurrent": 50534,
    "otheraccruedliabilitiescurrent": 1740,
    "finitelivedintangibleassetsgross": 1000000,
    "finitelivedintangibleassetsaccumulatedamortization": 416666,
    "finitelivedintangibleassetsnet": 583334,
    "impairmentofintangibleassetsfinitelived": 18000,
    "impairmentofintangibleassetfinitelivedstatementofincomeorcomprehensiveincomeextensibleenumeration": "http://fasb.org/us-gaap/2023#ResearchAndDevelopmentExpense",
    "finitelivedintangibleassetsamortizationexpensenexttwelvemonths": 100000,
    "finitelivedintangibleassetsamortizationexpenseyeartwo": 100000,
    "finitelivedintangibleassetsamortizationexpenseyearthree": 100000,
    "finitelivedintangibleassetsamortizationexpenseyearfour": 100000,
    "finitelivedintangibleassetsamortizationafteryearfour": 183000,
    "otherliabilityrelatedpartytypeextensibleenumeration": "http://fasb.org/srt/2023#OfficerMember",
    "otherreceivables": 1959000,
    "paymenttorelatedpartypermonth": 25000,
    "otherliabilities": 3523733,
    "creditofpriorresearchanddevelopmentexpense": 278000,
    "consultingorserviceagreementmonthlypayment": 14000,
    "numberofyearsincomefordistributionlimit": 2,
    "dateoffinancialstatementsanddistributionperiodmaximum": "P6M",
    "stockissuedduringperiodsharesstockoptionsexercised": 170833,
    "valuationallowancedeferredtaxassetchangeinamount": 6216000,
    "operatinglosscarryforwards": 17891000,
    "taxcreditcarryforwardamount": 321000,
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.21,
    "deferredtaxassetcapitalizationofresearchanddevelopmentcosts": 4617000,
    "deferredtaxassetsoperatinglosscarryforwards": 4276000,
    "deferredtaxassetstaxdeferredexpenseaccruedexpensesandother": 175000,
    "deferredtaxassetstaxcreditcarryforwardsresearch": 321000,
    "deferredtaxassetstaxdeferredexpensecompensationandbenefitssharebasedcompensationcost": 289000,
    "deferredtaxassetsinprocessresearchanddevelopment": 1104000,
    "deferredtaxassetsgoodwillandintangibleassets": 51000,
    "deferredtaxassetsgross": 6216000,
    "deferredtaxassetsvaluationallowance": 6216000,
    "incometaxreconciliationincometaxexpensebenefitatfederalstatutoryincometaxrate": -1824000,
    "incometaxreconciliationnondeductibleexpense": 167000,
    "effectiveincometaxratereconciliationresearchanddevelopmentamount": -195000,
    "incometaxreconciliationstateandlocalincometaxes": 79000,
    "incometaxreconciliationchangeindeferredtaxassetsvaluationallowance": 1824000,
    "effectiveincometaxratereconciliationdeferredtrueupamount": -51000,
    "numberoflicenseandsupplyagreementsentered": 9
  },
  {
    "date": "2020-12-31",
    "symbol": "QNRX",
    "period": "FY",
    "cashandcashequivalents": 16964000,
    "othercurrentreceivables": 284000,
    "currentassets": 17248000,
    "restrictedcashandcashequivalents": 322000,
    "rightofuseassetsunderoperatinglease": 705000,
    "othernoncurrentreceivables": 72000,
    "propertyplantandequipment": 1232000,
    "noncurrentassets": 2331000,
    "assets": 19579000,
    "tradeandothercurrentpayablestotradesuppliers": 389000,
    "currentleaseliabilities": 369000,
    "othercurrentpayables": 2228000,
    "currentliabilities": 2986000,
    "noncurrentpayables": 1222000,
    "noncurrentleaseliabilities": 391000,
    "noncurrentliabilities": 1613000,
    "additionalpaidincapital": 126838000,
    "reserveofsharebasedpayments": 16508000,
    "treasuryshares": 9425000,
    "retainedearnings": -118941000,
    "equity": -118941000,
    "equityandliabilities": 19579000,
    "numberofsharesauthorised": 500000000,
    "numberofsharesissued": 390949079,
    "numberofsharesoutstanding": 390949079,
    "researchanddevelopmentexpense": 5883000,
    "generalandadministrativeexpense": 8111000,
    "otherincome": -13994000,
    "profitlossfromoperatingactivities": -13994000,
    "financecosts": 4083000,
    "profitloss": -18077000,
    "basicanddilutedearningslosspershare": 0.049,
    "weightedaverageshares": 368078786,
    "issuanceofadsnetofissuecosts": 9194000,
    "increasedecreasethroughsharebasedpaymenttransactions": 739000,
    "exerciseofshareoptionsandwarrants": 8287000,
    "foreigncurrencyconveniencetranslation": 4659000,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": 1326000,
    "depreciationofrightofuseassetsunderoperatinglease": 369000,
    "adjustmentsfordepreciationandamortisationexpense": 350000,
    "financeexpenses": 88000,
    "adjustmentsforsharebasedpayments": 738000,
    "adjustmentsforincreasedecreaseintradeandotherpayables": 2722000,
    "adjustmentsforreconcileprofitloss": 2941000,
    "adjustmentsfordecreaseincreaseintradeandotherreceivables": 207000,
    "adjustmentsforincreasedecreaseinotheroperatingpayables": -621000,
    "operatingactivitiesforchangesinassetandliability": -414000,
    "interestreceivedclassifiedasoperatingactivities": 64000,
    "cashflowsfromusedinoperatingactivities": -15486000,
    "proceedsfromsalesofpropertyplantandequipmentclassifiedasinvestingactivities": 35000,
    "proceedsfromrestricteddeposit": 6000,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 329000,
    "cashflowsfromusedininvestingactivities": -288000,
    "proceedsfromexerciseofoptions": 4615000,
    "paymentsofleaseliabilitiesclassifiedasfinancingactivities": 441000,
    "proceedsfromissuingshares": 9194000,
    "cashflowsfromusedinfinancingactivities": 13368000,
    "effectofexchangeratechangesoncashandcashequivalents": 1264000,
    "increasedecreaseincashandcashequivalents": -1142000,
    "depreciationratepropertyplantandequipment": 0.15,
    "financialliabilitiesrelatedtowarrantstoads": -1222000,
    "tradeandothercurrentreceivables": 15000,
    "governmentauthorities": 56000,
    "currentprepaidexpenses": 213000,
    "tradeandotherreceivables": 284000,
    "rightofuseassets": 1507000,
    "deductionsrightofuseassets": -17000,
    "additionstorightofuseassets": 56000,
    "accumulateddepreciationrightuseofassets": 705000,
    "additionstoaccumulateddepreciation": 369000,
    "totalaccumulateddepreciation": 802000,
    "accumulateddepreciationrightuseofassetsothercurrencies": 219000,
    "interestexpenseonleaseliabilities": 88000,
    "depreciationrightofuseassets": 369000,
    "comprehensivelossonoperatingleases": 457000,
    "noncurrentleaseliability": 391000,
    "leaseliabilities": 760000,
    "undiscountedoperatingleasepaymentstobereceived": 822000,
    "propertyplantandequipmentcost": 3102000,
    "additionsotherthanthroughbusinesscombinationspropertyplantandequipment": 329000,
    "disposalspropertyplantandequipment": -96000,
    "accumulateddepreciationpropertyplantequipment": 1870000,
    "accumulateddepreciationchargeforyearpropertyplantequipment": 350000,
    "deductionsaccumulateddepreciationchargeforyearpropertyplantequipment": -61000,
    "accumulateddepreciationcost": 1232000,
    "accumulateddepreciationcostconveniencetranslation": 384000,
    "shorttermemployeebenefitsaccruals": 810000,
    "accruedexpenses": 1391000,
    "payablesother": 27000,
    "numberofshareissuedandoutstanding": 390949079,
    "issuanceofshares": 100000000,
    "numberofexerciseofshareoptions": 66861280,
    "numberofoptionsshareoutstanding": 48895227,
    "weightedaverageexercisepriceofoptionsoutstandinginsharebasedpaymentarrangement": 0.3,
    "numberofoptionsforfeitedinsharebasedpaymentarrangement": 617572,
    "weightedaverageexercisepriceofoptionsforfeitedinsharebasedpaymentarrangement": 1.25,
    "numberofoptionsexpiredinsharebasedpaymentarrangement": 1990305,
    "weightedaverageexercisepriceofoptionsexpiredinsharebasedpaymentarrangement": 1.14,
    "numberofoptionsgrantedinsharebasedpaymentarrangement": 29409600,
    "weightedaverageexercisepriceofoptionsgrantedinsharebasedpaymentarrangement": 0.09,
    "exercisepriceofshareoptionsoutstandingminimum": 1.8,
    "exercisepriceofshareoptionsoutstandingmaximum": 2.1,
    "numberofoptionssharesoutstanding": 48895227,
    "weightedaverageremainingcontractuallifeofshareoptionsoutstanding": "P8Y36D",
    "numberofoptionsexercisableshareoutstanding": 21915304,
    "weightedaverageremainingcontractuallifeofshareoptionsexercisableoutstanding": "P6Y109D",
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.8753,
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.0185,
    "descriptionofoptionslifeshareoptionsgranted": "P10Y",
    "otherpayables": 542000,
    "tradeandotherpayables": 542000,
    "numberofemployee": 4,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 3432000,
    "noofpeople": 5,
    "keymanagementpersonnelcompensationincludingdirectors": 2003000,
    "researchanddevelopmentexpenses": 1328000,
    "transfersofgeneralandadministrativeexpensestoentityrelatedpartytransactions": -177000,
    "transfersofexpensestoentityrelatedpartytransactions": -177000,
    "averageforeignexchangerate": 3.215,
    "averageleaseterm": "P3Y",
    "numberoftreasurysharesissued": 2641693,
    "fairvalueoftheoptionsgrants": 1653882000,
    "taxrateeffectofforeigntaxrates": 0.23,
    "weightedtaxrate": 0.21,
    "taxlossescarryforward": 99883000,
    "leaseagreementtermdescription": "These leases have an average life of three years with no option to extend the contract. The Company has the right to terminate the agreement before the end of the three years and will be required to pay an early termination penalty of between one to three months of the lease.",
    "futureminimumleasefeespayable2021": 45000,
    "futureminimumleasefeespayable2022": 26000,
    "futureminimumleasefeespayable2023": 7000,
    "descriptionofcurrentcommitmentsorintentionstoprovidesupporttosubsidiary": "Israel-United States Binational Industrial Research and Development Foundation (BIRD) for the support of research and development activities. The Company is obligated to pay royalties to BIRD, amounting to 5% of the gross sales of the products and other related revenues developed from such activities, up to an amount of 150% from the grant received from BIRD by the Company indexed to the U.S. consumer price index.",
    "restrictedbankdeposittosecurecreditcardpayments": 52000,
    "restrictedbankdeposittosecurerentpayment": 164000,
    "entityregistrantname": "Cellect Biotechnology Ltd.",
    "documenttype": "20-F",
    "currentfiscalyearenddate": "--12-31",
    "entitycommonstocksharesoutstanding": 390949079,
    "amendmentflag": "false",
    "entitycentralindexkey": 1671502,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityfilercategory": "Non-accelerated Filer",
    "entitywellknownseasonedissuer": "No",
    "documentperiodenddate": "2020-12-31",
    "documentfiscalyearfocus": 2020,
    "documentfiscalperiodfocus": "FY",
    "entityemerginggrowthcompany": "true",
    "entityshellcompany": "false",
    "entityextransitionperiod": "false",
    "documentannualreport": "true",
    "documentshellcompanyreport": "false",
    "documenttransitionreport": "false",
    "entityfilenumber": "001-37846",
    "entityincorporationstatecountrycode": "L3",
    "entityinteractivedatacurrent": "Yes"
  },
  {
    "date": "2019-12-30",
    "symbol": "QNRX",
    "period": "FY",
    "cashandcashequivalents": 18106000,
    "othercurrentreceivables": 469000,
    "currentassets": 18575000,
    "restrictedcashandcashequivalents": 328000,
    "rightofuseassetsunderoperatinglease": 1035000,
    "othernoncurrentreceivables": 94000,
    "propertyplantandequipment": 1288000,
    "noncurrentassets": 2745000,
    "assets": 21320000,
    "tradeandothercurrentpayablestotradesuppliers": 158000,
    "leaseliabilities": 396000,
    "othercurrentpayables": 3080000,
    "currentliabilities": 3634000,
    "noncurrentpayables": 2172000,
    "noncurrentleaseliabilities": 677000,
    "noncurrentliabilities": 2849000,
    "additionalpaidincapital": 108598000,
    "reserveofsharebasedpayments": 16528000,
    "treasuryshares": 9425000,
    "retainedearnings": -100864000,
    "equity": -100864000,
    "equityandliabilities": 21320000,
    "numberofsharesauthorised": 500000000,
    "numberofsharesissued": 224087799,
    "numberofsharesoutstanding": 224087799,
    "researchanddevelopmentexpense": -12122000,
    "generalandadministrativeexpense": -10210000,
    "otherincome": 22332000,
    "profitlossfromoperatingactivities": -22332000,
    "financeincome": 6993000,
    "financecosts": 1469000,
    "profitloss": -16808000,
    "basicanddilutedearningslosspershare": 0.079,
    "weightedaverageshares": 212642505,
    "issuanceofadswarrantsnetofissuecosts": 15014000,
    "increasedecreasethroughsharebasedpaymenttransactions": 2708000,
    "foreigncurrencyconveniencetranslation": 4293000,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": -1036000,
    "depreciationofrightofuseassetsunderoperatinglease": 433000,
    "adjustmentsfordepreciationandamortisationexpense": 373000,
    "financeexpenses": 128000,
    "issuanceexpenses": 1621000,
    "adjustmentsforsharebasedpayments": 2708000,
    "adjustmentsforincreasedecreaseintradeandotherpayables": -8643000,
    "adjustmentsforreconcileprofitloss": -2344000,
    "adjustmentsfordecreaseincreaseintradeandotherreceivables": 385000,
    "adjustmentsforincreasedecreaseinotheroperatingpayables": -1663000,
    "operatingactivitiesforchangesinassetandliability": -1278000,
    "interestreceivedclassifiedasoperatingactivities": 93000,
    "cashflowsfromusedinoperatingactivities": -20337000,
    "proceedsfromsalesofpropertyplantandequipmentclassifiedasinvestingactivities": 6000,
    "proceedsfromrestricteddeposit": 9000,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 123000,
    "cashflowsfromusedininvestingactivities": -108000,
    "paymentsofleaseliabilitiesclassifiedasfinancingactivities": 522000,
    "proceedsfromissuingshares": 22393000,
    "cashflowsfromusedinfinancingactivities": 21871000,
    "effectofexchangeratechangesoncashandcashequivalents": -1129000,
    "increasedecreaseincashandcashequivalents": 297000,
    "depreciationratepropertyplantandequipment": 0.15,
    "financialliabilitiesrelatedtowarrantstoads": -2172000,
    "rightofuseassets": 1468000,
    "deductionsrightofuseassets": 146000,
    "accumulateddepreciationrightuseofassets": 1035000,
    "additionstorightofuseassets": 433000,
    "totalaccumulateddepreciation": 433000,
    "accumulateddepreciationrightuseofassetsothercurrencies": 299000,
    "interestexpenseonleaseliabilities": 128000,
    "expenserelatingtoleasesoflowvalueassetsforwhichrecognitionexemptionhasbeenused": 196000,
    "depreciationrightofuseassets": 433000,
    "comprehensivelossonoperatingleases": 757000,
    "currentleaseliabilities": 396000,
    "totalleaseliabilities": 1073000,
    "undiscountedoperatingleasepaymentstobereceived": 1174000,
    "tradeandothercurrentreceivables": 9000,
    "governmentauthorities": 258000,
    "currentprepaidexpenses": 202000,
    "tradeandotherreceivables": 469000,
    "propertyplantandequipmentcost": 2869000,
    "additionsotherthanthroughbusinesscombinationspropertyplantandequipment": 123000,
    "disposalspropertyplantandequipment": -6000,
    "accumulateddepreciationpropertyplantequipment": 1581000,
    "accumulateddepreciationchargeforyearpropertyplantequipment": 376000,
    "deductionsaccumulateddepreciationchargeforyearpropertyplantequipment": -3000,
    "accumulateddepreciationcost": 1288000,
    "accumulateddepreciationcostconveniencetranslation": 373000,
    "shorttermemployeebenefitsaccruals": 877000,
    "accruedexpenses": 2025000,
    "payablesother": 178000,
    "numberofshareissuedandoutstanding": 224087799,
    "numberofissuanceofsharesandwarrants": 93673000,
    "numberofoptionsshareoutstanding": 22093504,
    "weightedaverageexercisepriceofoptionsoutstandinginsharebasedpaymentarrangement": 0.59,
    "numberofoptionsforfeitedinsharebasedpaymentarrangement": 4556865,
    "weightedaverageexercisepriceofoptionsforfeitedinsharebasedpaymentarrangement": 0.7,
    "numberofoptionsexpiredinsharebasedpaymentarrangement": 671438,
    "weightedaverageexercisepriceofoptionsexpiredinsharebasedpaymentarrangement": 1.21,
    "numberofoptionsgrantedinsharebasedpaymentarrangement": 14307660,
    "weightedaverageexercisepriceofoptionsgrantedinsharebasedpaymentarrangement": 0.12,
    "exercisepriceofshareoptionsoutstandingminimum": 1.8,
    "exercisepriceofshareoptionsoutstandingmaximum": 2.1,
    "numberofoptionssharesoutstanding": 22093504,
    "weightedaverageremainingcontractuallifeofshareoptionsoutstanding": "P8Y73D",
    "numberofoptionsexercisableshareoutstanding": 13730238,
    "weightedaverageremainingcontractuallifeofshareoptionsexercisableoutstanding": "P7Y292D",
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.7775,
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.0214,
    "descriptionofoptionslifeshareoptionsgranted": "P10Y",
    "otherpayables": 108000,
    "tradeandotherpayables": 108000,
    "numberofemployee": 4,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 5190000,
    "noofpeople": 7,
    "keymanagementpersonnelcompensationincludingdirectors": 636000,
    "researchanddevelopmentexpenses": 1326000,
    "transfersofgeneralandadministrativeexpensestoentityrelatedpartytransactions": 1304000,
    "transfersofexpensestoentityrelatedpartytransactions": 1304000,
    "operatingleaseterm": "P12M",
    "averageleaseterm": "P3Y",
    "numberoftreasurysharesissued": 2641693,
    "fairvalueoftheoptionsgrants": 4676895,
    "taxrateeffectofforeigntaxrates": 0.23,
    "weightedtaxrate": 0.21,
    "taxlossescarryforward": 79263,
    "leaseagreementtermdescription": "These leases have an average life of three years with no option to extend the contract. The Company has the right to terminate the agreement before the end of the three years and will be required to pay an early termination penalty of between one to three months of the lease.",
    "futureminimumleasefeespayable2020": 58000,
    "futureminimumleasefeespayable2021": 38000,
    "futureminimumleasefeespayable2022": 23000,
    "futureminimumleasefeespayable2023": 6000,
    "descriptionofcurrentcommitmentsorintentionstoprovidesupporttosubsidiary": "Israel-United States Binational Industrial Research and Development Foundation (BIRD) for the support of research and development activities. The Company is obligated to pay royalties to BIRD, amounting to 5% of the gross sales of the products and other related revenues developed from such activities, up to an amount of 150% from the grant received from BIRD by the Company indexed to the U.S. consumer price index.",
    "restrictedbankdeposittosecurecreditcardpayments": 51000,
    "restrictedbankdeposittosecurerentpayment": 163000,
    "issuanceofaggregateamericandepositaryshares": 1000000,
    "ordinarysharesinregisteredndirectoffering": 100,
    "purchasepriceperads": 3,
    "descriptionofbusinessacquisition": "The Company will acquire from Canndoc all rights to the use of Canndoc&#x2019;s products for the reduction of opioid usage, including accumulated data, as well as on-going and pipeline of clinical trials. In addition, Canndoc will supply to the Company, over the course of the next five years, with a minimum of 6 tons of GMP pharma grade cannabis products with a value of $18 million USD. The Company will have the option to extend the agreement for an additional period of 5 years, until 2029.",
    "issuetoamericandepositaryreceipts": 1023720,
    "percentageofsharecapitalonpartiallydilutedbasis": 0.19,
    "entityregistrantname": "Cellect Biotechnology Ltd.",
    "documenttype": "20-F",
    "currentfiscalyearenddate": "--12-31",
    "entitycommonstocksharesoutstanding": 224087799,
    "amendmentflag": "false",
    "entitycentralindexkey": 1671502,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityfilercategory": "Non-accelerated Filer",
    "entitywellknownseasonedissuer": "No",
    "documentperiodenddate": "2019-12-31",
    "documentfiscalyearfocus": 2019,
    "documentfiscalperiodfocus": "FY",
    "entityemerginggrowthcompany": "true",
    "entityshellcompany": "false",
    "entityextransitionperiod": "false",
    "documentannualreport": "true",
    "documentshellcompanyreport": "false",
    "documenttransitionreport": "false",
    "entityfilenumber": "001-37846",
    "entityincorporationstatecountrycode": "L3",
    "entityinteractivedatacurrent": "Yes"
  }
]